Clinical outcome of routine treatment of patients with Pelvic Inflammatory Disease and/or Tubo Ovarial Abcess in the presence or absence of Mycoplasma genitalium (MG)

Clinical outcome of routine treatment of patients with Pelvic Inflammatory Disease and/or Tubo Ovarial Abcess in the presence or absence of Mycoplasma genitalium (MG) - Clinical outcome of PID- and TOA-patients with and without MG

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54533

Enrollment

120

Registered

2020-07-02

Start date

2021-04-01

Completion date

Unknown

Last updated

2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PID

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients with PID or TOA

Exclusion criteria

Exclusion criteria: Pregnancy Hypersensitivity to antibiotics given as standard treatment Not being able to understand information provided in Dutch or English

Design outcomes

Primary

Measure	Time frame
Clinical outcome of PID and/or TOA is based on fever, abdominal pain, cervical leucorrhoea during speculum examination, painful genitalia interna, other clinical signs and CRP.	—

Secondary

Measure	Time frame
1) The presence and persistence of MG-DNA in vaginal swabs. 2) Antibiotic resistance prevalence in MG positive cases.	—

Countries

Netherlands

Outcome results